Change search
ReferencesLink to record
Permanent link

Direct link
Double-blind comparison of sertraline and placebo in stroke patients with minor depression and less severe major depression
Show others and affiliations
2005 (English)In: Journal of Clinical Psychiatry, ISSN 0160-6689, E-ISSN 1555-2101, Vol. 66, no 6, 708-716 p.Article in journal (Refereed) Published
Abstract [en]

Background: Poststroke depression is a frequent condition and important to treat. The aim of this trial was to study the efficacy and tolerability of sertraline. Method: In 4 Swedish stroke centers, 123 patients (aged 70.7 +/- 9.9 years) were enrolled during the period September 1998 to January 2001 in a randomized, double-blind, placebo-controlled 26-week trial, at a mean of 128 +/- 97 days (range, 3-375 days) after stroke, if they fulfilled DSM-IV criteria of major depressive episode (N = 76) or minor depressive disorder (N = 47). The primary efficacy variable was a changed in depression assessed by the Montgomery-Asberg Depression Rating Scale. The Emotional Distress Scale (EDS) was administered and the occurrence of emotionalism and quality of life (QoL) were assessed, as well as neurologic recovery. Efficacy analyses were intention-to-treat, short-term (week 6) and long-term (week 26). Results: Of the 123 patients, 62 were treated with sertraline (50-100 mg/day) and 61 with placebo. Both groups improved substantially, with no differences between the treatments, either for major depressive episode or minor depressive disorder, or for short- or long-term antidepressant effect and neurologic outcome. EDS revealed a better outcome with sertraline at week 6 (p <.05). At week 26, the improvement in QoL was better in sertraline patients (p <.05) and there was a trend for emotionalism (p =.07). No serious side effects were seen. Conclusion: Poststroke depression as measured by a conventional depression rating scale improved over time irrespective of treatment. Positive effects specific to sertraline were identified in emotional distress, emotionalism, and QoL. The study indicates that poststroke emotional reactions comprise depression and other domains susceptible to pharmacologic therapy.

Place, publisher, year, edition, pages
2005. Vol. 66, no 6, 708-716 p.
Keyword [en]
poststroke depression, fluoxetine, mortality, therapy, trial, mood, nortriptyline, multicenter, citalopram, recovery
URN: urn:nbn:se:kth:diva-14846ISI: 000229989000006ScopusID: 2-s2.0-21744444273OAI: diva2:332887
QC 20100525Available from: 2010-08-05 Created: 2010-08-05Bibliographically approved

Open Access in DiVA

No full text


Search in DiVA

By author/editor
Näsman, Per
By organisation
Safety Research
In the same journal
Journal of Clinical Psychiatry

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Total: 22 hits
ReferencesLink to record
Permanent link

Direct link